Helus Pharma Inc., a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), has completed a legal name change from Cybin Inc., effective Oct. 1, 2026. The change was approved by shareholders at the company's annual and special meeting on Sept. 22 and follows the adoption of the Helus Pharma business name in January. The company's common shares will continue trading under the ticker HELP on the Nasdaq Global Market and Cboe Canada, with no action required by existing shareholders.
The name change reflects Helus Pharma's anticipated transition from a clinical-stage discovery and development company to a commercial-ready pharmaceutical company. Founded in 2019, Helus Pharma is committed to helping minds heal by developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. These investigational treatments aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions.
Helus Pharma's lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. The company is also developing HLP004, a proprietary NSA in Phase 2 for generalized anxiety disorder, and maintains an extensive research portfolio of investigational NSAs. With class-leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that provide durable improvements in mental health.
The rebranding could have significant implications for investors and the mental health industry. As the company moves closer to commercialization, the new name may better reflect its focus on innovative therapies. For more information about Helus Pharma, visit www.helus.com.
The announcement was disseminated on behalf of Helus Pharma and may include paid advertising. The company's shares trade under Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP). To view the full press release, visit https://ibn.fm/rrJFh.
MissionIR, a specialized communications platform focused on enhancing the visibility of private and public companies within the investment community, distributed the news. It is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and a full array of tailored corporate communications solutions.
